CMS Eases Up on MA Data Collection, But Unknowns Remain

As efforts to contain the outbreak of COVID-19 continue to evolve, the Trump administration on March 30 issued a series of new flexibilities aimed at increasing hospital and provider capacity. At the same time, CMS provided some respite to Medicare Advantage and Part D plans dealing with the crisis by suspending audit and quality reporting activities so that plans and states can focus on providing care to the increasing number of beneficiaries affected by the new coronavirus. While those changes will enable CMS to issue star quality ratings for 2021, the potential impact of COVID-19 on payment rates for next year remained unclear.

COVID-19, declared a pandemic last month, has had more than 200,000 documented cases in the U.S. — with the most cases and deaths confirmed in New York state — according to the latest figures from the Johns Hopkins University & Medicine Coronavirus Resource Center. President Donald Trump on March 13 declared a national emergency as a result of the pandemic, allowing for waivers of certain Medicare and Medicaid requirements to address the outbreak that have been rolled out over the past few weeks.

© 2024 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

achp-logo
April 18

ACHP: Final Rule Checks ‘Untethered’ Agent, Broker Fees Impacting Competition

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
April 18

News Briefs: UnitedHealth Reaffirms Full-Year Earnings Guidance Despite Cyberattack Impact

READ MORE
older-black-man
April 18

How Does MA Plan Design Impact Enrollment, Equity?

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today